Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Top Ranked Growth Stocks To Buy For July 22nd

Published 07/21/2019, 11:35 PM
Updated 07/09/2023, 06:31 AM
EBAY
-
COR
-

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 22nd:

eBay Inc (NASDAQ:EBAY). (EBAY): This commerce platforms operator, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.1% over the last 60 days.

eBay Inc. Price and Consensus

eBay Inc. Price and Consensus

eBay Inc. price-consensus-chart | eBay Inc. Quote

eBay has a PEG ratio of 1.57 compared with 2.21 for the industry. The company possesses a Growth Score of B.

eBay Inc. PEG Ratio (TTM)

eBay Inc. PEG Ratio (TTM)

eBay Inc. peg-ratio-ttm | eBay Inc. Quote

Merck & Co., Inc. (MRK):This healthcare solutions provider, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.

Merck has a PEG ratio of 1.73, compared with 1.92 for the industry. The company possesses a Growth Score of B.

Magellan Health, Inc. (MGLN): This healthcare management services provider, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2% over the last 60 days.

Magellan Health has a PEG ratio of 0.73, compared with 1.35 for the industry. The company possesses a Growth Score of A.

AmerisourceBergen (NYSE:ABC) Corporation (ABC): This pharmaceutical products distributor, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.

AmerisourceBergen has a PEG ratio of 1.67, compared with 1.75 for the industry. The company possesses a Growth Score of A.

See the full list of top ranked stocks here.

Learn more about the Growth score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Merck & Co., Inc. (MRK): Free Stock Analysis Report

Magellan Health, Inc. (MGLN): Free Stock Analysis Report

eBay Inc. (EBAY): Free Stock Analysis Report

AmerisourceBergen Corporation (ABC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.